.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Express Scripts
Cipla
Covington
Harvard Business School
Novartis
US Department of Justice
McKesson
Healthtrust

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022106

« Back to Dashboard
NDA 022106 describes DORIBAX, which is a drug marketed by Shionogi Inc and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the DORIBAX profile page.

The generic ingredient in DORIBAX is doripenem. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the doripenem profile page.

Summary for 022106

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 022106

Ingredient-typeCarbapenems

Suppliers and Packaging for NDA: 022106

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DORIBAX
doripenem
INJECTABLE;IV (INFUSION) 022106 NDA Shionogi Inc. 59630-309 59630-309-10 10 VIAL, SINGLE-USE in 1 CARTON (59630-309-10) > 10 mL in 1 VIAL, SINGLE-USE (59630-309-01)
DORIBAX
doripenem
INJECTABLE;IV (INFUSION) 022106 NDA Shionogi Inc. 59630-320 59630-320-10 10 VIAL, SINGLE-USE in 1 CARTON (59630-320-10) > 10 mL in 1 VIAL, SINGLE-USE (59630-320-01)

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;IV (INFUSION)Strength500MG/VIAL
Approval Date:Oct 12, 2007TE:RLD:Yes
Patent:► SubscribePatent Expiration:Mar 30, 2021Product Flag?YSubstance Flag?YDelist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;IV (INFUSION)Strength250MG/VIAL
Approval Date:Oct 5, 2010TE:RLD:Yes
Patent:► SubscribePatent Expiration:Mar 30, 2021Product Flag?YSubstance Flag?YDelist Request?

Expired Orange Book Patents for NDA: 022106

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shionogi Inc
DORIBAX
doripenem
INJECTABLE;IV (INFUSION)022106-001Oct 12, 2007► Subscribe► Subscribe
Shionogi Inc
DORIBAX
doripenem
INJECTABLE;IV (INFUSION)022106-002Oct 5, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Merck
Express Scripts
Accenture
US Army
Chinese Patent Office
Boehringer Ingelheim
Mallinckrodt
Cipla
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot